Korean J Blood Transfus.
2022 Dec;33(3):182-184. 10.17945/kjbt.2022.33.3.1 8 2.
Is Leukoreduction Needed for Plasma Products?
- Affiliations
-
- 1Department of Laboratory Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea
- 2Department of Laboratory Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea
- 3Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea
- 4Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2537225
- DOI: http://doi.org/10.17945/kjbt.2022.33.3.1 8 2
Abstract
- Leukoreduction is a process in which the white blood cells (WBCs) in cellular products are intentionally reduced to bring down the risk of adverse transfusion reactions, such as febrile nonhemolytic transfusion reactions or human leukocyte antigen alloimmunization. So far, Korea has not considered leukoreduction of plasma products. However there have been recommendations for leukoreduction to improve patient outcomes. The authors have experience in measuring WBCs and WBC fragment counts in plasma products and have shown that the WBC and their fragments could be efficiently removed using leukoreduction filters. Hence, it may be beneficial to begin discussions on the necessity of using leukoreduction of plasma products.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Reduction of Influenza A (H1N1) Virus Through a Leukoreduction Filter
- The Status of Use of Leukoreduced Blood Products in Korean Hospitals
- The Current Global Status and Production Trends of Plasma Fractionation
- Blood Coagulation Products and Other Hemostatic Agents
- The how's and why's of evidence based plasma therapy
